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To the Editor: 
The paper by Wildiers et al1 raises some challenges in terms of ethical approaches to 
end-of-life phase III studies and their interpretation. Although to be commended for 
undertaking a large multi-site randomised controlled trial in palliative care, there are 
fundamental questions that do need to be addressed before the first steps can be taken 
to adopt these findings into practice 
 
There is a need to understand the natural history of secretions in the terminal stages of 
a life-limiting illness.2 What happens when there is no pharmacological intervention? 
What is the contribution of the cumulative effect of other medications with anti-
cholinergic side-effects?3 What is the contribution of co-morbid illnesses such as 
cardiac or respiratory failure? How many people were receiving parenteral fluids?  
How many had widespread oedema or hypoalbuminaemia? Given the large number of 
observational studies that have been done in hospice and palliative care, it is 
disappointing that the natural history of secretions at the end of life is poorly defined.  
 
Combining all these factors, what are the characteristics of people who do not get 
secretions compared to those who do, and in the light of this paper, which factors are 
associated more strongly with a clinically meaningful response when pharmacological 
therapy is introduced? This is brought into sharper focus when the data to support 
reduction in the volume of secretions in other settings using these medications 
suggests that they are relatively ineffective.4 The study by Wildiers et al1  lacked a 
placebo arm. Given the current state of knowledge in this field, the high risk of side 
effects with each of these medications, and the background evidence that intervention 
and placebo may have the same effect on terminal secretions in this population, the 
lack of a placebo is a significant omission. 
 
Also of concern is lack of information on standardisation. Given the enormous effort 
to put this study together, why wasn’t the intervention blinded? How was the 
assessment of the primary outcome standardised across multiple sites? Nurses are an 
exceptionally well trained group of clinicians in hospice and palliative care, however 
we cannot necessarily depend upon their ability to discern, far example, pulmonary 
oedema requiring diuretics from terminal secretions. Re-treatment decisions were also 
left to nurses’ subjective decisions and could likely be influenced by worried family 
members or others in the room.  
 
As this was a multi-site study, standardisation across sites is an imperative for a 
primary outcome measure that is inherently subjective and measured by a third party. 
While we commend the authors for trying to conduct a large prospective study 
addressing such a fundamental area to our discipline, the importance of the question 
increases the importance of ensuring that the study design and methods are able to be 
transferred across multiple sites. 
 
These basic study design issues are magnified further by lack of informed consent in 
this study. Ethically, how can people not be consented when it is unknown whether 
the net clinical benefit of these interventions (extrapolated almost exclusively from 
pre-operative approaches in well people to normal physiological secretions) offer 
benefit that the patient or their caregivers will be able to perceive? There is sufficient 
equipoise to do the study. If an argument ‘that the therapy is in widespread use’ was 
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an acceptable yardstick, then almost any phase III study in hospice and palliative care 
of off-licence prescribing could be justified without prior patient or proxy consent.  
 
Consent in this setting is not a barrier to participation but rather an invitation by a 
researcher to a person or his/her family to engage in a process of exploration in an 
open and informed way. The communities in which we live have asked all clinical 
researchers, irrespective of how widespread the intervention being evaluated is in 
existing practice, to engage in a respectful and inclusive dialogue about an 
individual’s involvement in research. Failure to engage in seeking consent risks 
compromising the community’s willingness to allow hospice and palliative care 
clinical research in the future, even if that research is to directly improve the quality 
of care. The fact that the subject is unconscious does not revoke this fundamental 
right unless the intervention is immediately life saving. 
 
Options that have been demonstrated in clinical research including hospice and 
palliative care settings to work well, are acceptable to Institutional Review Boards 
and Research Ethics Committees,5 and include: 
(i) pre-consent for someone likely to experience a condition of interest at some time-
point in the future when they are unable to provide consent has been dealt with in an 
ethical manner without compromising the study;6 or 
(ii). proxy consent by an adequately appointed patient advocate or next-of-kin.7 
 
How should these results be interpreted by clinicians? One could argue that the 
medications are equally ineffective in controlling secretions given a lack of knowledge 
of the natural history of the symptom and little basic science evidence to support their 
use in the pathological state of dying,. The understanding of the natural history of 
secretions in this setting, appropriate consenting procedures and the inclusion of a 
blinded placebo is not only desirable but it is mandatory if the findings of this study 
are to influence practice.2  
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